Original Medicare (parts A and B) generally covers BCG treatments for specific types of bladder cancer when deemed medically necessary by a healthcare team. Part A covers the treatment if it is ...
Tecentriq combined with BCG did not enhance outcomes for high-risk NMIBC patients compared to BCG alone, with similar event-free survival rates. The ALBAN trial reported higher rates of side effects ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
What Is Imfinzi, and Why Does It Matter? Imfinzi (durvalumab) is a prescription immunotherapy medicine used to treat different types of cancer. The FDA has approved the combination of Imfinzi and ...
Allegheny Health Network Department of Urology is offering a gemcitabine intravesical system to provide the therapy for BCG-unresponsive NMIBC. Ongoing shortages of Bacillus Calmette-Guérin (BCG) and ...
Anktiva plus BCG aims to treat BCG-unresponsive NMIBC with papillary disease, potentially reducing radical cystectomy need. The treatment showed high rates of surgery avoidance and disease-free ...
Please provide your email address to receive an email when new articles are posted on . Patients with high-risk non-muscle-invasive bladder cancer who received durvalumab plus BCG had improved DFS.
A simple urine test developed by researchers at Stanford Medicine and the VA Palo Alto Health Care System can diagnose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results